Sidera Bio is an early-stage biotechnology company based in Denmark that has not yet publicly disclosed details of its therapeutic pipeline. Led by chief executive Keld Flintholm Jørgensen—formerly chief business officer at Lundbeck and a veteran of Roche—the startup is positioning itself as an ambitious new entrant in the Nordic life-sciences ecosystem. Although product specifics remain undisclosed, the company’s ability to attract a blue-chip investor syndicate suggests a focus on high-value therapeutic programs. The firm secured roughly 700 million Danish kroner ($109 million) in Series A capital, one of the largest early-stage biotech financings ever completed in Denmark. This sizeable war chest provides a multi-year runway to advance its R&D efforts and build a robust preclinical and clinical pipeline. The financing also signals growing international appetite for Scandinavian biotech innovation. With strong financial backing and experienced leadership, Sidera Bio is expected to accelerate hiring and expand laboratory operations as it moves its undisclosed programs toward key development milestones.

Total raised

$110M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2025